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fifteen-year-old adolescents, utilizing pharmacy students
as instructors.
METHODS: A cost-effectiveness study is conducted to
determine the cost per student who passed the knowledge
based exam on tobacco use, after attending the lecture
sessions of the tobacco outreach program. The primary
outcome of interest is the number of adolescents able to
pass the post-test, compared to the number able to pass
the pre-test. The following direct costs were collected:
supplies; materials; travel; consultant fees; primary inves-
tigator salary; coordinator salary; student teacher salary
and training; cost of classroom/space, and value of do-
nated goods. Only the incremental costs and outcomes
are utilized to calculate the CE ratio. No indirect costs or
discounting is included in the analysis.
RESULTS: A total of 132 students participated in the
program during a period of one year. The average cost
per student is $389.00. Pre-test and post-test are adminis-
tered to seventy-eight of these students. The cost-effec-
tiveness ratio per student who received a higher grade on
the post-test versus the pre-test is $689.59. The cost-effec-
tiveness ratio per student who received a grade greater
than seventy on the post-test compared to the pre-test is
$2,167.28.
CONCLUSIONS: This study evaluates the impact on the
post-test scores compared to the pre-test scores only. It
does not evaluate the impact of this program either on
behavioral changes associated with tobacco use, or on
the indirect benefit of being exposed to positive role mod-
els, the students from the college of pharmacy. The aver-
age per-student program cost of this study population is
consistent with published literature. However, very little
literature exists to determine if the CE ratios are within
the standards of other drug abuse educational programs.
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OBJECTIVE: To perform a retrospective economic anal-
ysis of The Coronary Angioplasty Amlodipine Restenosis
Study (CAPARES), in order to evaluate the pharmaco-
economic profile associated with the use of amlodipine in
patients undergoing angioplasty from the perspective of
the UK National Health Service
METHODS: A decision analysis was undertaken to track
the experiences of patients admitted for angioplasty who
were prescribed amlodipine versus those administered
placebo. The analysis modeled a four-month time period,
which included an initial hospitalization for angioplasty,
outpatient follow-up care and any re-admissions for car-
diovascular events. The CAPARES trial provided the out-
come data for the amlodipine and placebo patients. Out-
comes tracked in the analysis included MI, repeat PTCA,
CABG, and all-cause mortality. Economic data for inpa-
tient stays, procedures, physician services, laboratory
tests and pharmaceuticals were obtained from published
data, and a physician panel was used to estimate the
quantity of outpatient resource consumption.
RESULTS: The total expected cost per patient using and
not using amlodipine was £3,833 and £4,035, respec-
tively, resulting in a net cost savings of £202 over the
four-month time period. The cost savings is primarily due
to savings in inpatient costs due to the reduction in ad-
verse events requiring repeat revascularization and other
events requiring inpatient stays.
CONCLUSION: This analysis concludes that in addition
to the favourable clinical outcome for angioplasty pa-
tients using amlodipine versus placebo demonstrated in
the CAPARES trial, a net savings in overall costs may
also be realized, resulting in dominance.
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OBJECTIVES: MEDENOX, a multinational double-
blind, placebo-controlled trial (n  1102) of venous
thromboembolism (VTE) prophylaxis among hospital-
ized, acutely ill. Medical patients revealed a lower inci-
dence of VTE among patients receiving enoxaparin 40
mg once daily for 6-14 days relative to placebo (5.5%
versus 14.9% p  .001). Conducted in Europe and Can-
ada, the trial did not include a prospective economic
component. The purpose of this study was to model the
cost-effectiveness of VTE prophylaxis with enoxaparin in
a US health-care environment from the payer perspective.
METHODS: From a national sample of US hospital sum-
mary bills, we extracted records (n  374,855) of dis-
charges matching MEDENOX diagnostic/demographic
characteristics (primary diagnoses: acute infectious dis-
ease, acute respiratory failure, or heart failure, mean age:
73 years). With these data we estimated a multivariate
model of admission cost. Regression parameters were in-
corporated in a pharmacoeconomic model of hospital ad-
mission for patients treated with or without enoxaparin
per the MEDENOX protocol. Using Monte Carlo simu-
lation, the model projected cost of admission as a func-
tion of diagnosis, length of stay, VTE prophylaxis/no
prophylaxis. Outcome measures included cost of admis-
sion, cost for VTE prophylaxis, and incremental prophy-
laxis cost per VTE avoided. Not included were potential
downstream costs for inpatient or post-hospital VTE
treatment.
RESULTS: In the base case analysis, VTE prophylaxis ac-
